Andriana Kaliora
Athens, 17671, Greece
NCT Number: NCT05687539
The main aim of this study is to establish whether Mastiha products ameliorate functional dyspepsia symptoms.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Athens, 17671, Greece
Functional dyspepsia has an approximate prevalence of 20% and is one of the main causes of upper abdominal discomfort. Its pathogenesis remain unclear and therapeutic options remain limited with patients seeking alternative therapies in herbal remedies. Mastiha has been proven to significantly improve symptoms in patients with functional dyspepsia compared to placebo. In the present study, the investigators aim to determine whether Mastiha capsules or Mastiha water have a better effect on the improvement of functional dyspepsia symptoms. Therefore, the investigators designed a randomized, three-way cross-over clinical trial. Fifty patients with functional dyspepsia, will be randomized over three treatment sequences of 30 days each, separated by 14-day washout periods. The three treatments will be: Mastiha capsules, Mastiha water or Mastiha free treatment. The primary outcome, which will be assessed by intention to treat, will be the Leuven Postprandial Distress Scale, a validated instrument for the assessment of symptoms in functional dyspepsia, supported by the European Medicines Agency.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
functional dyspepsia diagnosis according to
Exclusion criteria
10ml of mastiha water before every meal for one month
2x350mg mastiha capsules before every meal for one month
Time frame: 1 month
The change in Leuven Postprandial Distress Scale will be evaluated at follow-up. LPDS minimum score is 0 and maximum 32. Higher scores mean a worse outcome.
Time frame: 1 month
Change in quality of life at follow-up as assessed via the EQ-5D-5L questionnaire. EQ-5D-5L has a scale from 0 to 100, with higher scores meaning better outcomes.
Time frame: 1 month
The percentage of patients that changed drug dose of medicines for functional dyspepsia will be evaluated at follow-up.
Time frame: 1 month
Change in anxiety at follow-up as assessed via the GAD-7 ANXIETY questionnaire. GAD-7 ANXIETY has a scale from 0 to 21, with higher scores meaning worse outcomes.
Harokopio University
Other
The Effect of Mastiha Products on Functional Dyspepsia. A Randomised Crossover Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06732453
Digestive System Diseases, Functional Dyspepsia
Charlotte, North Carolina, United States
View Trial DetailsNCT04526119
Functional Dyspepsia
Matsumoto, Nagano, Japan
View Trial DetailsNCT05513040
Functional Dyspepsia
Lanzhou, Gansu, China
View Trial DetailsNCT03176927
Chronic Nausea, Diabetic Gastroparesis
Nashville, Tennessee, United States
View Trial Details